|25. In adults receiving treatment with a biologic, we conditionally recommend against discontinuation of the biologic.|Very low to low|66|
|27. In adults receiving treatment with a biologic, we conditionally recommend against tapering of the biologic dose as a standard approach.|Very low|65|
|28. In adults receiving treatment with an originator TNFi, we strongly recommend continuing treatment with the originator TNFi over mandated switching to its biosimilar.|Very low|63|